Group 1 - The core viewpoint of the articles highlights the significant financial performance of BeiGene, with a total revenue of 2.433 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 44.73% [1] - Gross profit reached 2.103 billion USD, an increase of 48.33% compared to the previous year [1] - The net profit for the period was 95.59 million USD, a turnaround from a net loss of 372 million USD in the same period last year, with basic earnings per share of 0.07 USD [1] Group 2 - The increase in total revenue is primarily attributed to the sales growth of the company's self-developed products, including Baiyueze® and Tislelizumab, as well as the sales of licensed products, mainly from Amgen [1] - For the six months ending June 30, 2025, product revenue net increased by 44.5% to 2.4106 billion USD, up from 1.6681 billion USD in the same period last year [1] - Baiyueze® global sales reached 1.7415 billion USD, a 54.7% increase year-on-year, with U.S. sales totaling 1.2469 billion USD, up 50.1% from 830.8 million USD in the previous year [2] Group 3 - The robust growth in Baiyueze® sales is attributed to strong demand across all indications and moderate gains from net pricing [2] - Baiyueze® continues to maintain a leading market share among new patients in the BTK inhibitor class due to its differentiated and best-in-class clinical characteristics [2]

目录 美国 证券交易委员会 Washington, D.C. 20549 表格 10-K （选择一项） ☒ 根据 1934 年证券交易法第 13 条或第 15 条(d)节的年度报告 截至 2024 年 12 月 31 日的财政年度 或 ☐ 根据 1934 年证券交易法第 13 条或第 15 条(d)节的过渡报告 百济神州有限公司 （注册人章程载明的确切名称） （注册成立或组建的州或其他司法管辖区） （美国国家税务局雇主身份识别号码） c/o Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman 开曼群岛 KY1-1108 （主要行政办事处地址，包括邮政编码） +1 (345) 949 4123 过渡期从 至 交易委员会递交编号：001-37686 BEIGENE, LTD. （注册人的电话号码，包括地区编码） 根据本法案第 12（b）条注册的证券： | 各类别名称 | 交易代码 | 各证券交易所名称 | | --- | --- | --- | | 每股美国存托股份相当于 13 股普通股，每 ...